DRTS Stock Forecast & Price Target

Alpha Tau Medical is favorably positioned because Alpha DaRT is showing compelling clinical efficacy across multiple oncology settings, including 100% ORR, 18.2 months of median overall survival, and 5.4 months of median progression-free survival in HNSCC with pembrolizumab, while also showing no Alpha DaRT-associated serious adverse events. Its pipeline has several near-term catalysts in 2H26 and late 2026 or early 2027, including REGAIN in recurrent GBM, IMPACT in pancreatic cancer, a U.S. prostate cancer pilot, and topline ReSTART data in cSCC, which could support a Breakthrough Device/PMA path. Despite the 2Q26 net loss of $45.8M, the company is advancing trials in underserved populations such as immunocompromised cSCC patients, where a localized, repeatable treatment could address major unmet need and broaden commercial potential.

Alpha Tau Medical is viewed negatively because its value depends overwhelmingly on Alpha DaRT, a clinical-stage platform that still faces meaningful clinical, regulatory, and commercialization uncertainty across indications like SCC, GBM, and head & neck cancer. The cited valuations hinge on aggressive assumptions, including a 15% discount rate, 2% terminal growth, and approval probabilities that still leave material execution risk, while cash of $80.2M to $104.8M may not be sufficient to offset prolonged development needs. The outlook is further weakened by potential dilution, uncertain U.S. approval, and the risk that competition, market size, or penetration limits prevent meaningful commercial success even if trials are positive.